Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism
about
Applications of SPR for the characterization of molecules important in the pathogenesis and treatment of neurodegenerative diseasesNatalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosisTherapeutic decisions in multiple sclerosis: moving beyond efficacyiNKT Cells in Secondary Progressive Multiple Sclerosis Patients Display Pro-inflammatory Profiles.Therapeutic interference with leukocyte recirculation in multiple sclerosis.Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuationEffect of natalizumab treatment on circulating plasmacytoid dendritic cells: a cross-sectional observational study in patients with multiple sclerosis.Treating multiple sclerosis with monoclonal antibodies: a 2013 update.TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or NatalizumabWhat do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens.Treating multiple sclerosis with natalizumab.A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis.Characterization of IL-17AA and IL-17FF in rheumatoid arthritis and multiple sclerosis.Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment.
P2860
Q26860077-F5166EB5-4496-4798-ADD5-8F3233869890Q28484467-7FB99E32-C6F4-4966-A5FA-AC540DB80822Q28541039-98CB71A4-571F-48D2-8F00-22CF65D376E1Q30368046-D548D090-ADC1-4EE5-A7E5-BD0CA4BDD997Q30884219-9E5A843B-E6E1-4DD8-A11C-7AB7BEE34291Q31108462-AA4603FB-BD03-4F7F-83EA-CAF2C1E935FBQ33562198-00647D56-6080-4543-97F6-72B439793FC2Q33975585-0D6CB704-DAF3-4B6B-A758-045A42A47E2CQ34330211-6B565D81-D5FF-4E14-A142-30DC5B7E1C22Q34418098-664F4794-9C47-4FE6-A7E3-A45827BE4B05Q36396476-F20981B5-62EA-420C-9D4E-4F49DC513C7AQ37286272-E3816F9F-167D-4EE7-829A-0107EFDF7351Q37957123-B8BC0288-85CC-4A50-A392-E2DFFD64B143Q42181576-F83D09E4-5BCC-4A71-BA44-FD0899B85788Q50898570-1182B017-8988-438F-ABD7-A6B20A803545Q51515919-1AEBD82D-7ABE-4C59-A451-8F9A945187C9Q52849668-53ABE9A9-556E-47CC-BE83-1C4369A7D346
P2860
Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Treatment with natalizumab in ...... nges in inflammatory mechanism
@ast
Treatment with natalizumab in ...... nges in inflammatory mechanism
@en
type
label
Treatment with natalizumab in ...... nges in inflammatory mechanism
@ast
Treatment with natalizumab in ...... nges in inflammatory mechanism
@en
prefLabel
Treatment with natalizumab in ...... nges in inflammatory mechanism
@ast
Treatment with natalizumab in ...... nges in inflammatory mechanism
@en
P2093
P2860
P1476
Treatment with natalizumab in ...... nges in inflammatory mechanism
@en
P2093
Beatriz Chamorro
Celia Oreja-Guevara
Jaime Ramos-Cejudo
Luis Rodriguez de Antonio
P2860
P2888
P304
P356
10.1007/S10875-011-9522-X
P577
2011-04-14T00:00:00Z